Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Net Margin (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Net Margin for 5 consecutive years, with 50.66% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin rose 27997.0% year-over-year to 50.66%; the TTM value through Mar 2026 reached 76.29%, up 34615.0%, while the annual FY2025 figure was 126.24%, 47884.0% up from the prior year.
  • Net Margin hit 50.66% in Q1 2026 for Phathom Pharmaceuticals, down from 36.72% in the prior quarter.
  • Across five years, Net Margin topped out at 1473.65% in Q1 2022 and bottomed at 11665.1% in Q4 2023.
  • Average Net Margin over 5 years is 1085.29%, with a median of 126.02% recorded in 2025.
  • Year-over-year, Net Margin tumbled -1223745bps in 2023 and then soared 1141396bps in 2024.
  • Phathom Pharmaceuticals' Net Margin stood at 572.35% in 2022, then plummeted by -2138bps to 11665.1% in 2023, then soared by 98bps to 251.15% in 2024, then surged by 85bps to 36.72% in 2025, then plummeted by -38bps to 50.66% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 50.66%, 36.72%, and 60.53% for Q1 2026, Q4 2025, and Q3 2025 respectively.